Longeveron announced the appointment of global pharmaceutical leader Wa’el Hashad as Chief Executive Officer. Hashad will assume the role of Chief Executive Officer effective March 1, 2023. Following Hashad joining Longeveron, current Interim Chief Executive Officer Chris Min, M.D., Ph.D., will continue in his role as Chief Medical Officer. Hashad brings to Longeveron over 35 years of leadership in global pharmaceutical and biotechnology companies. Most recently, he was President and Chief Executive Officer at Avanir Pharmaceuticals.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LGVN:
- Longeveron Appoints Wa’el Hashad as Chief Executive Officer
- Longeveron announces publication of final data from ELPIS I trial
- Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
- UPDATE — Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones
- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones